We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TNFA

Price
14.00
Stock movement up
+- (%)
Company name
TNF Pharmaceuticals, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
1.99M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-93.75%
3 year return
-87.01%
5 year return
-76.53%
10 year return
-72.20%
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

TNFA does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open13.50
Daily high14.80
Daily low13.50
Daily Volume14K
All-time high6347520.00
1y analyst estimate-
Beta2.32
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
TNFAS&P500
Current price drop from All-time high-100.00%-3.04%
Highest price drop-100.00%-56.47%
Date of highest drop20 Jun 20259 Mar 2009
Avg drop from high-82.24%-11.04%
Avg time to new high579 days12 days
Max time to new high2870 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
TNFA (TNF Pharmaceuticals, Inc.) company logo
Marketcap
1.99M
Marketcap category
Small-cap
Description
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.
Employees
6
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...